Interpretation of the expert consensus on traditional Chinese medicine diagnosis and treatment of irritable bowel syndrome(2024)
-
摘要: 《肠易激综合征中医诊疗专家共识(2024)》(以下简称2024版《共识》)是2020年11月由中华中医药学会脾胃病分会在北京牵头，联合全国30家三级甲等医院及高校、科研院所共同修订的关于肠易激综合征(IBS)中医诊疗专家共识。该共识呈现出三大重要特点：①内容全面：2024版《共识》内容包括IBS的诊断、病因病机、辨证分型、临床治疗、疗效评定、预防调摄、转归与随访等多方面，为中医诊疗IBS提供了全面的指导；②紧跟前沿动态：结合IBS国内外最新研究进展，新增了“西医诊疗进展概述”“中医药循证医学进展”“难点问题分析及中医药优势”等多个专栏；③重视经验传承：传承中医名家学术经验，新增了“现代名家学术经验”专栏。本文将详细解读《共识》的更新及重点内容，以期进一步推动其在临床实践中的应用。Abstract: The expert consensus on traditional Chinese medicine diagnosis and treatment of irritable bowel syndrome(2024) is an expert consensus on traditional Chinese medicine(TCM) diagnosis and treatment led by the Spleen and Stomach Diseases Branch of the China Association of Chinese Medicine in November 2020 in Beijing, in collaboration with thirty tertiary hospitals and universities and research institutes across the country. It presents three important features: ① it is comprehensive, covering the spectrum of irritable bowel syndrome(IBS) diagnosis, etiology, pathogenesis, classification, clinical treatment protocols, efficacy assessment, advancements in TCM evidence-based medicine, preventative measures, and follow-up care, thereby offering an exhaustive guide for TCM practitioners in managing IBS.② it is cutting-edge, with additional sections that align with global diagnostic and therapeutic frontiers, including an "Overview of Western Medicine Diagnosis and Treatment Progress", "Progress of Evidence-Based Medicine in TCM", and an "Analysis of Challenges and Advantages of TCM". ③ it emphasizes experience inheritance and innovation, with a dedicated section on "Modern Academic Experience of Eminent TCM Practitioners". This article delves into the updates and highlights of the 2024 expert consensus, aiming to promote its broader clinical application.
-
-
[1] Mearin F, Lacy BE, Chang L, et al. Bowel Disorders[J]. Gastroenterology, 2016: S0016-5085(16)00222-5.
[2] Almario CV, Sharabi E, Chey WD, et al. Prevalence and Burden of Illness of Rome Ⅳ Irritable Bowel Syndrome in the United States: Results From a Nationwide Cross-Sectional Study[J]. Gastroenterology, 2023, 165(6): 1475-1487. doi: 10.1053/j.gastro.2023.08.010
[3] Hanna-Jairala I, Drossman DA. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When[J]. Am J Gastroenterol, 2024, 119(7): 1272-1284. doi: 10.14309/ajg.0000000000002800
[4] Barbaro MR, Cremon C, Marasco G, et al. Molecular Mechanisms Underlying Loss of Vascular and Epithelial Integrity in Irritable Bowel Syndrome[J]. Gastroenterology, 2024: S0016-S5085(24)05204-1.
[5] Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome[J]. Am J Gastroenterol, 2021, 116(1): 17-44. doi: 10.14309/ajg.0000000000001036
[6] Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome[J]. Gut, 2021, 70(7): 1214-1240. doi: 10.1136/gutjnl-2021-324598
[7] Bosman MHMA, Weerts ZZRM, Snijkers JTW, et al. The Socioeconomic Impact of Irritable Bowel Syndrome: An Analysis of Direct and Indirect Health Care Costs[J]. Clin Gastroenterol Hepatol, 2023, 21(10): 2660-2669. doi: 10.1016/j.cgh.2023.01.017
[8] 中华中医药学会脾胃病分会. 肠易激综合征中医诊疗专家共识意见(2017)[J]. 中医杂志, 2017, 58(18): 1614-1620.
[9] 中华中医药学会脾胃病分会. 肠易激综合征中医诊疗专家共识(2024)[J]. 中医杂志, 2024, 65(18): 1948-1956.
[10] 中华医学会消化病学分会胃肠功能性疾病协作组, 中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志, 2020, 40(12): 803-818.
[11] 国家食品药品监督管理总局. 总局关于发布中药新药用于肠易激综合征临床研究技术指导原则等5个临床研究技术指导原则的通告(2017年第217号)[EB/ OL]. (2017-12-27)[2018-02-10].
https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20171227183101142.html .[12] 国家中医药管理局, 国家卫生健康委员会. 国家中医药管理局、国家卫生健康委员会关于印发《中医病证分类与代码》和《中医临床诊疗术语》的通知[EB/OL]. (2020-11-16)[2023-02-01].
https://www.gov.cn/zhengce/zhengceku/2020-11/24/content_5563703.htm .[13] 白光. 国医大师周学文应用复方石榴皮煎剂联合七情辨证治疗腹泻型肠易激综合征经验[J]. 中国中西医结合消化杂志, 2019, 27(12): 883-886. doi: 10.3969/j.issn.1671-038X.2019.12.01
[14] 谷诺诺, 王凯星, 杨倩, 等. 李佃贵教授基于浊毒理论治疗肠易激综合征经验[J]. 四川中医, 2017, 35(6): 3-5.
[15] 李登帅, 杜斌, 单兆伟. 单兆伟教授运用脾胃升降理论治疗肠易激综合征经验[J]. 四川中医, 2017, 35(5): 22-24.
[16] 马青, 单兆伟. 单兆伟教授治疗腹泻型肠易激综合征临证经验撷菁[J]. 四川中医, 2015, 33(12): 8-9.
[17] Black CJ, Ford AC. Irritable bowel syndrome: a spotlight on future research needs[J]. Lancet Gastroenterol Hepatol, 2021, 6(6): 419-422. doi: 10.1016/S2468-1253(21)00131-X
[18] Moayyedi P, Andrews CN, MacQueen G, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome(IBS)[J]. J Can Assoc Gastroenterol, 2019, 2(1): 6-29. doi: 10.1093/jcag/gwy071
[19] Ford AC, Lacy BE, Harris LA, et al. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis[J]. Am J Gastroenterol, 2019, 114(1): 21-39. doi: 10.1038/s41395-018-0222-5
[20] Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2016, 44(7): 693-703. doi: 10.1111/apt.13746
[21] Lembo A, Weber HC, Farraye FA. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder[J]. Drugs, 2003, 63(18): 1895-1905. doi: 10.2165/00003495-200363180-00002
[22] Nyhlin H, Bang C, Elsborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome[J]. Scand J Gastroenterol, 2004, 39(2): 119-126. doi: 10.1080/00365520310006748
[23] Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress[J]. Aliment Pharmacol Ther, 1997, 11(2): 395-402. doi: 10.1046/j.1365-2036.1997.142318000.x
[24] 中华中医药学会脾胃病分会. 脾胃病症状量化标准专家共识意见(2017)[J]. 中华中医药杂志, 2017, 32(8): 3590-3596.
[25] Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure[J]. Dig Dis Sci, 1998, 43(2): 400-411. doi: 10.1023/A:1018831127942
[26] 李鲁, 王红妹, 沈毅. SF-36健康调查量表中文版的研制及其性能测试[J]. 中华预防医学杂志, 2002, 36(2): 109-113.
[27] Zung WW. A rating instrument for anxiety disorders[J]. Psychosomatics, 1971, 12(6): 371-379. doi: 10.1016/S0033-3182(71)71479-0
[28] 黄金龙, 张明. 肠易激综合征患者个性结构、焦虑度及抑郁度测评[J]. 广东医学, 2006, 27(11): 1696-1697.
[29] Tang XD, Zhang SS, Hou XH, et al. Post-marketing Re-evaluation of Tongxiening Granules(痛泻宁颗粒)in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial[J]. Chin J Integr Med, 2019, 25(12): 887-894. doi: 10.1007/s11655-019-3030-x
-
计量
- 文章访问数: 1586
- PDF下载数: 826
- 施引文献: 0
下载: